Vimarsana
Biggest News Aggregation in the World

Page 5 - Current Reports News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Current Reports. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Current Reports Today - Breaking & Trending Today

Sunway Group Selects Rimini Street's Software Support and Managed Services to Fund and Staff AI and CX Projects - Vimarsana News

Sunway Group Selects Rimini Street's Software Support and Managed Services to Fund and Staff AI and CX Projects

Sunway Group Selects Rimini Street's Software Support and Managed Services to Fund and Staff AI and CX Projects

U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma - Vimarsana News

U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma

Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted approval for Breyanzi ® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma ...

Thermon Group Holdings, Inc.: Thermon Reports Fourth Quarter Fiscal 2024 Results - Vimarsana News

Thermon Group Holdings, Inc.: Thermon Reports Fourth Quarter Fiscal 2024 Results

Record Revenue, Adjusted EBITDA, and Adjusted EPS for Fiscal 2024Grew Revenue from Diversified End Markets to 68% of Total Revenue in Fiscal 2024Introducing Fiscal 2025 Revenue Guidance of $527 million

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma - Vimarsana News

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Approval based on results from CheckMate -901, the first Phase 3 trial in this patient population with an immunotherapy-chemotherapy combination to demonstrate survival benefit versus...

Stardust Power Announces Further Key Management - Vimarsana News

Stardust Power Announces Further Key Management

Chief Commercial Officer and Director of Accounting to strengthen management team...